Neurocrine Biosciences Announces FDA Approval Of INGREZZA Capsules For The Treatment Of Chorea Associated With Huntington's Disease
Portfolio Pulse from Happy Mohamed
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has announced that the U.S. Food and Drug Administration (FDA) has approved INGREZZA capsules for the treatment of adults with chorea associated with Huntington's disease. The approval is supported by data from two clinical studies, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. The drug demonstrated a three-times greater improvement in chorea severity compared to placebo.
August 18, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' INGREZZA has received FDA approval for the treatment of Huntington's disease. This could potentially boost the company's revenues as it opens up a new market for the drug.
The FDA approval of INGREZZA for the treatment of Huntington's disease is a significant milestone for Neurocrine Biosciences. This opens up a new market for the drug, which could potentially lead to increased sales and revenues for the company. The positive results from the clinical trials also boost the company's reputation and credibility in the pharmaceutical industry.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100